Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?

Kenneth Blum, Mark S. Gold, Luis Llanos-Gomez, Rehan Jalali, Panayotis K. Thanos, Abdalla Bowirrat, William B. Downs, Debasis Bagchi, Eric R. Braverman, David Baron, Alphonso Kenison Roy and Rajendra D. Badgaiyan
Additional contact information
Kenneth Blum: Center for Psychiatry, Medicine & Primary Care (Office of the Provost), Division of Addiction Research & Education, Western University Health Science, Pomona, CA 91766, USA
Mark S. Gold: Department of Psychiatry, School of Medicine, Tulane University, New Orleans, LA 70118, USA
Luis Llanos-Gomez: The Kenneth Blum Behavioral & Neurogenetic Institute, Division of Ivitalize Inc., Austin, TX 78701, USA
Rehan Jalali: The Kenneth Blum Behavioral & Neurogenetic Institute, Division of Ivitalize Inc., Austin, TX 78701, USA
Panayotis K. Thanos: Department of Psychology & Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Research Institute on Addictions, University at Buffalo, Buffalo, NY 14260, USA
Abdalla Bowirrat: Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel 40700, Israel
William B. Downs: Division of Precision Nutrition, Victory Nutrition International, Bonita Springs, FL 34135, USA
Debasis Bagchi: Division of Precision Nutrition, Victory Nutrition International, Bonita Springs, FL 34135, USA
Eric R. Braverman: Division of Clinical Neurology, Path Foundation NY, New York, NY 10010, USA
David Baron: Center for Psychiatry, Medicine & Primary Care (Office of the Provost), Division of Addiction Research & Education, Western University Health Science, Pomona, CA 91766, USA
Alphonso Kenison Roy: Department of Psychiatry, School of Medicine, Tulane University, New Orleans, LA 70118, USA
Rajendra D. Badgaiyan: Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, Long School of Medicine, University of Texas Medical Center, San Antonio, TX 78249, USA

IJERPH, 2021, vol. 18, issue 18, 1-18

Abstract: Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise to reduce total fat mass. However, medications may have significant side effects and can be potentially fatal. Data Retrieval : This brief review, based on a PUBMED search of the key terms “Obesity” and” Sarcopenia,” will present evidence to corroborate the existence of Reward Deficiency Syndrome (RDS) in obesity and the involvement of catecholaminergic pathways in substance seeking behavior, particularly as it relates to carbohydrates cravings. Expert Opinion: The genetic basis and future genetic testing of children for risk of aberrant generalized craving behavior are considered a prevention method. Here we present evidence supporting the use of precursor amino acid therapy and modulation of enkephalinase, MOA , and COMT inhibition in key brain regions. Such treatments manifest in improved levels of dopamine/norepinephrine, GABA, serotonin, and enkephalins. We also present evidence substantiating insulin sensitivity enhancement via Chromium salts, which affect dopamine neuronal synthesis regulation. We believe our unique combination of natural ingredients will influence many pathways leading to the promotion of well-being and normal healthy metabolic functioning. Sarcopenia has been shown to reduce angiogenesis and possible cerebral blood flow. Exercise seems to provide a significant benefit to overcome this obesity-promoting loss of muscle density. Conclusion: Utilization of proposed nutrigenomic formulae based on coupling genetic obesity risk testing promotes generalized anti-craving of carbohydrates and can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention.

Keywords: obesity; nutrigenomics; resting-state functional connectivity; sarcopenia; BMI; percent body fat; hypodopaminergia; Reward Deficiency Syndrome (RDS) (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/18/9774/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/18/9774/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:18:p:9774-:d:637165

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().